ResearcherWestlake UniversityActive in the last 2 years

Dongchao Xu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5125679645. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2026: 2 papers

Papers 2

Securinine suppresses pancreatic cancer progression by activating the p38 MAPK pathway to upregulate CHOP and induce endoplasmic reticulum stress. Last author DOI 10.1016/j.bbadis.2026.168229 ↗
Targeting pancreatic cancer progression: The formononetin and salvianolic acid B combination suppresses JAK/STAT signaling via MBOAT2 downregulation. Co-author DOI 10.1016/j.joim.2026.05.003 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Mengyao Tian · 1 shared paper, 2026 · strength 0.39
- Paper Securinine suppresses pancreatic cancer progression by activating the p38 MAPK pathway to upregulate CHOP and induce en… DOI 10.1016/j.bbadis.2026.168229 ↗
Ying Xu · 1 shared paper, 2026 · strength 0.28
- Paper Targeting pancreatic cancer progression: The formononetin and salvianolic acid B combination suppresses JAK/STAT signal… DOI 10.1016/j.joim.2026.05.003 ↗
Yuehua Chen · 1 shared paper, 2026 · strength 0.28
- Paper Targeting pancreatic cancer progression: The formononetin and salvianolic acid B combination suppresses JAK/STAT signal… DOI 10.1016/j.joim.2026.05.003 ↗
Yu Wang · 1 shared paper, 2026 · strength 0.28
- Paper Targeting pancreatic cancer progression: The formononetin and salvianolic acid B combination suppresses JAK/STAT signal… DOI 10.1016/j.joim.2026.05.003 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.